Navigation Links
New Drug Combination is Able to Eradicate Breast Metastases in Mice
Date:12/17/2007

SAN ANTONIO, Dec. 17 /PRNewswire/ -- A novel combination of drugs was able to completely eradicate human breast metastases growing in mice, and shows promise for the effective treatment of patients with advanced metastatic breast cancer. Dr. Sophia Ran from Southern Illinois University School of Medicine presented the results of a study using nab-paclitaxel and bevacizumab to treat lymphatic and pulmonary metastases in female SCID mice.

Paclitaxel is a widely used cancer chemotherapy drug, originally derived from an extract of the yew tree. It can have severe side effects, some of which are related to the fact that it will not dissolve in water and has to be dissolved in organic solvents for injection. Nab-paclitaxel is a nanoparticle form of paclitaxel that is coated with a nonreactive protein, albumin, allowing it to be dissolved in water. This has reduced the side effects of the treatment, and also makes it more effective.

Bevacizumab is a monoclonal antibody against vascular endothelial growth factor A (VEGF-A), a protein that is involved in building new blood vessels. Tumors require new networks of blood vessels in order to grow.

The idea for this research came from the observation that, nf cells that survive treatment with chemotherapy, the stress of the treatment causes excess VEGF-A to be produced. The VEGF-A protects the cells against future chemotherapy, and also generates new blood vessels. Both mechanisms may contribute to tumor recurrence and metastatic spread following chemotherapy. This is the molecular basis for combining bevacizumab with nab-paclitaxel for the treatment of metastatic tumors.

For this study, human breast cancer cells were implanted into mammary fat pads (the mouse equivalent of breast tissue) of female mice. The implanted cells grew into tumors, and lymphatic and pulmonary metastases developed by the time that the drugs were administered.

The drug combination completely eradicated the original tumors, although bevacizumab alone had no effect, and nab-paclitaxel alone caused tumor regression for only 27 days, after which the tumors grew back.

The drug combination also completely eradicated metastases in the treated animals. Bevacizumab alone and nab-paclitaxel alone reduced the average number of metastases by no more than 50%.

The combination of bevacizumab and nab-paclitaxel is currently being tested in early trials of women with metastatic breast cancer.


'/>"/>
SOURCE San Antonio Breast Cancer Symposium
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. CuraGen and TopoTarget Initiate Phase I/II Clinical Trial of Belinostat (PXD101) Combination Therapy for Acute Myeloid Leukemia
2. Abbott and AstraZeneca Announce Selection of Next-Generation Fenofibrate ABT-335 and CRESTOR(R) Fixed-Dose Combination
3. Study Shows Combination Therapy Incorporating AVODART(R) and Tamsulosin Provides Continuous Symptom Improvement Over 2 Years
4. Xeloda XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium
5. Xeloda(R) XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium
6. Vion Pharmaceuticals Announces Initiation of a Phase I/II Trial of Cloretazine(R) (VNP40101M) in Combination with Temodar(R) in Adult Brain Tumors
7. New Phase 3 Study in Treatment-Naive Adults with HIV Evaluates Efficacy and Safety of Once-Daily PREZISTA(TM)/ritonavir vs. KALETRA(R) as Part of HIV Combination Therapy
8. New Data Show Ceftobiprole as Effective as Combination Therapy in Treating Patients With Complicated Skin Infections, Including MRSA
9. European Unions CHMP Issues Positive Opinion on PEGINTRON(TM) Combination Therapy for Retreating Hepatitis C Patients Who Failed Previous Therapy
10. Pharmasset Commences Dosing in 28-Day Combination Study of R7128 with Pegasys(R) plus Copegus(R) for Hepatitis C
11. New Data Show Ceftobiprole as Effective as Combination Therapy in Treating Patients with Diabetic Foot Infections
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... April 20, 2017  RXi Pharmaceuticals Corporation (NASDAQ: ... that address significant unmet medical needs, today announced ... Company,s consumer product development program, based on its ... for Investigative Dermatology (SID) 76 th Annual ... promote the sciences relevant to skin health and ...
(Date:4/20/2017)... 2017  AbbVie (NYSE: ABBV), a global biopharmaceutical ... chronic hepatitis C virus (HCV) infected patients with ... compensated cirrhosis (Child-Pugh A) achieved sustained virologic response ... its investigational, pan-genotypic regimen of glecaprevir/pibrentasvir (G/P). These ... 12 weeks of G/P treatment without ribavirin. Patients ...
(Date:4/20/2017)... Research and Markets has announced the addition of ... By Service (Manufacturing, Research), By Country, (Brazil, Mexico, Colombia, Argentina, ... to their offering. ... The Latin American pharmaceutical contract manufacturing services market is anticipated ... drug registration cost in Latin American countries and continuous economic ...
Breaking Medicine Technology:
(Date:4/25/2017)... ... April 25, 2017 , ... As pharmaceutical companies are held ... with process innovation in drug formulation and manufacturing. CoreRx offers its clients ... equipment in support of their development and manufacturing goals. , The company ...
(Date:4/25/2017)... ... April 25, 2017 , ... Back Pain Centers ... back pain with a reputable physician in their area, announces the launch of a ... information for patients who are looking for reputable physicians to help them with back ...
(Date:4/25/2017)... ... April 25, 2017 , ... Saad B. Chaudhary, MD is committed to providing the highest ... chronic problems, I focus on preventative care with all my patients to alleviate possible future ... always feel free to contact my office and my trained staff will assist you in ...
(Date:4/25/2017)... ... April 25, 2017 , ... Emergency Physician and Distinguished Professor of Emergency ... Series, Outliers in Writing, set to publish in summer 2017. , Dr. Bobrow, ... University of Arizona College of Medicine. He also serves as Medical Director for the ...
(Date:4/25/2017)... ... ... Vetoquinol USA® , a world-class developer of veterinarian-approved ... EQUISTRO line, at this week’s Rolex Kentucky Three-Day Event in Lexington. Flexadin UCII ... The scientifically-developed Flexadin UCII supports the body’s normal repair of cartilage and joints. ...
Breaking Medicine News(10 mins):